Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TPD52 as a Therapeutic Target Identified by Machine Learning Shapes the Immune Microenvironment in Breast Cancer

1 Jan 2025

Abstract excerpt

Breast cancer (BRCA) is one of the most common malignancies and a leading cause of cancer-related mortality among women globally. Despite advances in diagnosis and treatment, the heterogeneity of BRCA presents significant challenges for effective management and prognosis. Recent studies emphasise the critical role of the tumour microenvironment, particularly immune cells, in influencing tumour behaviour and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Ferroptosis and cancer prognosis
Share to Single-cell and spatial transcriptomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39757112
DOI: 10.1111/jcmm.70333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TPD52 as a Therapeutic Target Identified by Machine Learning Shapes the Immune Microenvironment in Breast CancerPMID 39757112Read ↗

TPD52 promotes breast cancer cell migration, invasion and proliferation via activation of the MAPK/ERK signaling pathwaySemantic proximity Read ↗

CD52 is a prognostic biomarker and correlated with immune features in breast cancerSemantic proximity Read ↗

Comprehensive Analysis of the Immune Microenvironment Reveals that CD52 is a Marker for Breast Cancer Treatment with Immune Checkpoint InhibitorsSemantic proximity Read ↗

Identification of a novel immune-related gene signature by single-cell and bulk sequencing for the prediction of the immune landscape and prognosis of breast cancerSemantic proximity Read ↗

Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patientsSemantic proximity Read ↗

Machine learning analysis reveals tumor heterogeneity and stromal-immune niches in breast cancerSemantic proximity Read ↗

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures.Semantic proximity Read ↗

CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor MicroenvironmentSemantic proximity Read ↗

Targeting Germline BRCA1-Associated Breast Cancer Through Transcriptome-Guided ImmunopreventionSemantic proximity Read ↗

<i>TP53</i> mutations promote immunogenic activity in breast cancerSemantic proximity Read ↗

CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancerSemantic proximity Read ↗

A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.